MOVE Medacta Group

Medacta announces the first MySpine Anchor procedure completed in the US

Medacta Group SA / Key word(s): Product Launch
Medacta announces the first MySpine Anchor procedure completed in the US

05.10.2022 / 19:00 CET/CEST


Media release

Medacta announces the first MySpine Anchor procedure completed in the US

CASTEL SAN PIETRO, Switzerland, October 5, 2022 - Medacta announces the successful completion of the first procedure in the United States.  This recently FDA-cleared technique utilizes MySpine Anchor patient-specific guides to accurately implant ® Pedicle Screws and M.U.S.T. SI Headless Screws to anchor long constructs in complex spine procedures.

The procedure was performed by Ivan E. LaMotta, M.D., Orthopaedic Spine Surgeon at Midlands Orthopaedics & Neurosurgery in Columbia, South Carolina, USA and co-designer surgeon of the MySpine Anchor guide.

MySpine Anchor represents the pinnacle of patient-matched technology. These patient-specific drill guides allow for the precise execution of the pre-planned S2AI, posterior SI, and sacral screw trajectories. The generous footprint of the guides makes robust surface contact with the S1 and S2 dorsal elements, which allows the surgeon to place sacropelvic fixation and posterior sacroiliac stabilization in the most effective and efficient way, without the need for intraoperative navigation. A true paradigm change for complex spine surgery,” says Dr. LaMotta.

MySpine Anchor, the latest addition to the ® platform, is Medacta’s patient-matched solution for posterior Sacro-iliac joint fixation, potentially improving the thoracolumbar fixation to help reduce lower back pain.

The MySpine Anchor guides are used to prepare the S2AI and SI pilot holes based on the 3D preoperative planning with the patient’s unique anatomy. During the planning phase the surgeon’s ability to personalize the screw trajectories and sizes can alleviate many intraoperative challenges, increases accuracy, and saves time in the OR. [1,2]

S2AI screw placement is really challenging and if I can do the screw placement safely, fast, and accurately without more dissection than I am used to, I think I must go for it. This is the reason why I use MySpine Anchor,” says Dr. Geert Mahieu, AZ Monica, Antwerp, Belgium, co-designer surgeon of the MySpine Anchor guide.

MySpine Anchor is part of Medacta’s , an advanced network of digital solutions designed to improve patient outcomes and healthcare efficiency. It is also supported by the comprehensive, tailored educational offerings provided by the . With an international network of expert surgeons, the M.O.R.E. Institute is at the forefront of education on spine procedures and products with personalized high-level educational pathways. With Medacta, the surgeon is never alone.

Discover more about and .

Contact

Medacta International SA

Gianluca Olgiati

Senior Director Global Marketing

Phone: 0

 

About Medacta

Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon experts globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.

[1] Landi et al. Spinal Neuronavigation and 3D-Printed Tubular  Guide for Pedicle Screw Placement: A  Really New Tool  to Improve Safety and Accuracy of the Surgical Technique? J  Spine 2015, 4:5

[2] Lamartina et al. Pedicle screw placement accuracy in thoracic and lumbar spinal surgery with a patient-matched targeting guide: a cadaveric study. Eur Spine J. 2015 Nov;24(7)


Additional features:

File:


End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone:
E-mail:
Internet:
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1456899

 
End of News EQS News Service

1456899  05.10.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1456899&application_name=news&site_id=research_pool
EN
05/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medacta Group

Maria Vara ... (+3)
  • Maria Vara
  • Oscar Haffen Lamm
  • Valliant Campagne

Suspension of coverage

From 2nd of June we are suspending coverage of companies below due to a reallocation of resources. Our prior estimates should no longer be used as an indicator for the company moving forward.INNATE PHARMAINVENTIVAMEDACTAMEDARTISONWARD MEDICALVALNEVA

Maria Vara
  • Maria Vara

Medacta: model update - Buy rating reiterated, unchanged CHF160 PT

We update our model following the publication of the company's annual report. No changes have been applied to our revenue forecast as FY 2024 results and 2025 guidance are aligned with our estimates. On the P&L, we have softened our S&M expenses expectation as these stood more towards 35.5%

 PRESS RELEASE

Medacta publishes 2025 Annual General Meeting invitation

Medacta Group SA / Key word(s): AGMEGM Medacta publishes 2025 Annual General Meeting invitation 08.04.2025 / 10:00 CET/CEST Press Release                     Medacta publishes 2025 Annual General Meeting invitation  CASTEL SAN PIETRO, 8 April 2025 – Medacta Group SA (“Medacta”, SIX:MOVE) published today the invitation to the Annual General Meeting (“AGM”) which will take place on Wednesday, 7 May 2025 at 11.00 a.m. at the Group premises in Via alla Rossa 6, Rancate, Switzerland. Shareholders can register to attend the Annual General Meeting in person but will also be abl...

Maria Vara
  • Maria Vara

Medacta: Exceptional FY2024 to fuel sustainable growth, adj. EBITDA hi...

Medacta reported preliminary unaudited FY 2024 revenue in early February; hence, the EUR590.6m figure was not a surprise. Nonetheless, we may highlight again that all four business lines delivered above the market growth with double-digit cc gains with a broad base geographical contribution. Gross

Maria Vara
  • Maria Vara

Medacta: expanding SportsMed footprint with Parcus Medical acquisition

Medacta expands its SportMeds footprint by acquiring Parcus Medical, a distinguished player with a diverse product family in sports medicine spanning the shoulder, knee, hip, and foot & ankle, with FY2024 unaudited revenues of USD16m. The acquisition not only expands Medacta's offering but also

ResearchPool Subscriptions

Get the most out of your insights

Get in touch